| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 7Developing evidence | 100.0% (7/7) | 42.9% (3/7) | -0.2% | -0.2% | -13.3% |
| 20D | 6Developing evidence | 100.0% (6/6) | 33.3% (2/6) | -13.9% | -10.0% | -29.4% |
| 60D | 6Developing evidence | 100.0% (6/6) | 0.0% (0/6) | -17.4% | -31.4% | -93.0% |
| 120D | 5Developing evidence | 100.0% (5/5) | 0.0% (0/5) | -69.5% | -65.0% | -106.6% |
COMPANY RESEARCH
Magle Chemoswed Holding AB
MAGLE.ST · Sweden · Healthcare · Biotechnology
INSIDER SIGNAL
Insider activity score：53.6 / 100
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Where the evidence comes from
The two kinds of evidence disagree: the purchases themselves carry bull lines (large purchases), while share price and trading argue against (price down over six months, price trails its sector); company results argue against (loss-making). No data is held for: company actions.
- The insider purchases themselvesBulllarge purchases2 checked, under the threshold
- Share price and tradingBearprice down over six months, price trails its sector
- Short sellers1 checked, under the threshold
- Company resultsBearloss-making1 missing
- Company actionsno data held
Bull case · the buying is informative
- Net purchases of €253k equal 37% of the company's market value (€688k): large for the size of the business.
Bear case · discount it
- Company resultsThe company is loss-making on the latest captured figures: profit margin −95%, return on equity −66%.
- Share price and tradingThe share price is down 90% over six months (three months −56%, one month +10.0%). Insiders have bought into a fall the market has not reversed.Record (nearest stored case: price 20% or more below its prior 52-week high): after 11,051 earlier disclosures like this, the median 60-session excess return was −3.2%, within 1 percentage point of all comparable disclosures (−2.6%).
- Share price and tradingOver three months the share price changed −56% and the median of 278 Healthcare companies changed −6.2%: 50 points behind. The market has marked this company down against its own sector.
Evidence still missing
- Only one reading of profitability is held (profit margin −95%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
Checked and under the threshold: 3
- BearNo insider sale is recorded in the same 180 days.
- EitherThe latest purchase is 28 days old. Bull up to 14 days, bear from 90.
- BearThe register of Finansinspektionen shows no published net short position in this company. Positions under 0.5% are never published, so this does not show that nobody is short.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
53.6 / 100
Latest recorded score
↑ +1.5 ptsversus the comparable snapshot on 2026-09-14 (35 calendar days apart)
- Recorded snapshots
- 36
- First snapshot
- 2026-08-26
Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.
- Purchase size+0.1 pts
- Recency+1.4 pts
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 58.1
- 52.1
- 57.9
- 55.4
- 53.6
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-08-26 | 58.1 |
| 2026-08-27 | 58.1 |
| 2026-08-28 | 58.1 |
| 2026-08-31 | 58.1 |
| 2026-09-01 | 58.1 |
| 2026-09-02 | 58.1 |
| 2026-09-03 | 58.1 |
| 2026-09-04 | 58.1 |
| 2026-09-07 | 52.1 |
| 2026-09-08 | 52.1 |
| 2026-09-09 | 52.1 |
| 2026-09-10 | 52.1 |
| 2026-09-11 | 52.1 |
| 2026-09-14 | 52.1 |
| 2026-09-23 | 60.8 |
| 2026-09-24 | 60.3 |
| 2026-09-25 | 59.7 |
| 2026-09-28 | 58.3 |
| 2026-09-29 | 57.9 |
| 2026-09-30 | 57.5 |
| 2026-10-01 | 57.1 |
| 2026-10-02 | 56.8 |
| 2026-10-03 | 56.8 |
| 2026-10-04 | 56.8 |
| 2026-10-05 | 55.9 |
| 2026-10-06 | 55.7 |
| 2026-10-07 | 55.4 |
| 2026-10-08 | 55.2 |
| 2026-10-09 | 55.0 |
| 2026-10-12 | 54.5 |
| 2026-10-13 | 54.3 |
| 2026-10-14 | 54.2 |
| 2026-10-15 | 54.0 |
| 2026-10-16 | 53.9 |
| 2026-10-18 | 53.8 |
| 2026-10-19 | 53.6 |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.600 | 21.0 |
| Qualified-buy size | 25% | 0.807 | 20.2 |
| Role informativeness (inverted) | 20% | 0.050 | 1.0 |
| Recency | 10% | 0.144 | 1.4 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
Why there is no buy signal
No qualifying open-market purchase disclosure is available in the current research window. This is not a sell signal.
The underlying disclosures remain available below for audit.
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #12 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (7d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 6Developing evidence | 100.0% (6/6) | 0.0% (0/6) | -2.2% | -4.2% | -10.3% |
| 20D | 6Developing evidence | 100.0% (6/6) | 0.0% (0/6) | -21.2% | -21.6% | -33.9% |
| 60D | 6Developing evidence | 100.0% (6/6) | 0.0% (0/6) | -22.4% | -38.3% | -92.9% |
| 120D | 5Developing evidence | 100.0% (5/5) | 0.0% (0/5) | -31.0% | -45.1% | -106.2% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing evidence | 100.0% (5/5) | 40.0% (2/5) | -2.2% | -0.4% | -10.3% |
| 20D | 5Developing evidence | 100.0% (5/5) | 0.0% (0/5) | -18.8% | -16.4% | -23.7% |
| 60D | 5Developing evidence | 100.0% (5/5) | 0.0% (0/5) | -22.4% | -38.8% | -93.4% |
| 120D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -28.6% | -46.0% | -106.7% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 235.4%
- Beta
- 0.33
- Avg daily volume
- SEK 74,306.3
VALUATION
- Market cap
- SEK 7.6M
- P/E
- —
FUNDAMENTALS
- Profit margin
- -94.9%
- ROE
- -66.3%
- Industry
- Biotechnology
Prices to 07 Oct 2026: price cache (Eulerpool). From OpenBB/yfinance, captured 16 Oct 2026: Market cap, Profit margin, ROE, Beta, Industry. It does not affect the insider score or rank.
Disclosed net short positions
The Finansinspektionen register, read 19 Oct 2026, publishes no net short position of 0.5% or more in this issuer. Positions below 0.5% are never published, so this is not evidence that nobody is short.
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
No qualifying purchase was filed in this period.
Buying size vs market trading
No daily prices and volumes have been captured for this stock yet.
Insider timeline
The current window holds no filing with a trade date.
Insider vs stock price
No daily prices and volumes have been captured for this stock yet.
Latest news
No news has been captured for this company.
Regulatory filings
The filing records held for this company carry no link to the original notice.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
The underlying filing feed is unavailable in this snapshot; this is not a claim that no filings exist.
Other disclosed transactions · excluded from score
The underlying filing feed is unavailable in this snapshot; this is not a claim that no filings exist.
Follow new disclosures
Subscribe to new Europe disclosures. These are market-wide RSS feeds, not company-specific alerts.
Snapshot & identity
- Snapshot date
- 2026-10-19
- Ticker
- MAGLE.ST
- ISIN
- SE0014401014
- Sector
- Healthcare
- Industry
- Biotechnology